On Sunday, May 11, President Donald Trump announced on Truth Social that he would sign an Executive Order today aimed at lowering prescription drug prices. The order refocuses the drug pricing debate, which often is centered around patents, on “equalizing” pricing among developed nations. In his social media post, Trump blamed pharmaceutical companies for chalking up the high price of drugs in the United States to research and development costs. “It was always difficult to explain and very embarrassing because, in fact, there was no correct or rightful answer,” Trump wrote. He also implied that Democrats have resisted efforts to lower prices due to campaign contributions from the industry and said the Order signed today will reduce drug prices “almost immediately, by 30% to 80%” via a “most favored nations” policy that will mandate U.S. citizens pay the same price as the nation paying the lowest price.
Recent Posts
- Other Barks and Bites for Friday, June 27: EGC Says ‘NERO CHAMPAGNE’ Unduly Exploits Protected Designation of Origin; SCOTUS Seeks SG Views on Skinny Label Issues in Hikma; and a Big Week for Copyrights and AI
- PTAB Designates Informative Director Review Decision Vacating Institution of Two Petitions Challenging Same Claims
- Stewart Grants Discretionary Denial Due to Patent Being Dismissed From Litigation
- U.S. Government’s Intervention in Patent Case Signals Good News for Patent Owners Seeking Injunctions
- Gaming Patent Litigation on Both Sides of the ‘v’ | IPWatchdog Unleashed